The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Impact of early tumor shrinkage on long-term outcome in metastatic colorectal cancer (mCRC) treated with 5FU plus irinotecan plus leucovorin (FOLFIRI) or capecitabine plus irinotecan XELIRI plus bevacizumab.
J. Ichante
No relevant relationships to disclose
A. Adenis
No relevant relationships to disclose
D. Malka
Consultant or Advisory Role - Roche
Honoraria - Roche
Research Funding - Roche
E. Francois
Consultant or Advisory Role - Roche
Honoraria - Roche
E. Boucher
No relevant relationships to disclose
B. Chauffert
No relevant relationships to disclose
J. Pignon
No relevant relationships to disclose
M. Ychou
Consultant or Advisory Role - Roche
Honoraria - Roche
J. Pierga
Consultant or Advisory Role - Roche
Honoraria - Roche
Research Funding - Roche
C. Montoto-Grillot
No relevant relationships to disclose
T. Conroy
Research Funding - Roche
M. Ducreux
Consultant or Advisory Role - Roche
Honoraria - Roche
Research Funding - Roche